!!! News CYTOMYX Holdings PLC !!! - 500 Beiträge pro Seite

[moz01]

RNS Number:8430V

Cytomyx Holdings PLC

26 February 2004

CYTOMYX HOLDINGS PLC

AGM STATEMENT

At the Annual General Meeting of Cytomyx Holdings Plc being held today, the Company`s Chairman, Dr William Mason, will make the following statement. "The highlights of the first quarter of the current financial year have been the completion of the acquisition of Clinomics Biosciences, Inc. and a placing with institutional investors to raise £1.9m to fund further development of the Group. Clinomics has built the world`s most extensive commercial database of highly characterised human biology samples and the Group expects strong demand for these new products and services from the pharmaceutical and drug discovery community in the future.
Clinomics` products make it possible for pharmaceutical researchers to link knowledge about genes and proteins to their relevance in human disease through the use of the Company`s patented high-throughput technology known as "tissue microarrays." These enable the imprinting of hundreds of individual human tissue samples onto a single microscope slide so that researchers can simultaneously
study protein levels in hundreds of individual tissue samples in parallel. Researchers can then draw conclusions as to the relevance of these protein levels in disease. Fully understanding the role of a protein or gene target in
human biology, in both normal and disease-specific cells is essential in the development of new drugs. An additional benefit to the Group will be the presence of an operation in the USA providing access to the world`s largest market for its products and research services.
Trading in the first quarter has been broadly in line with management`s expectations. Cytomyx Limited has seen a continued expansion of its new drug discovery related product line with the introduction of further ion channel cell lines and the launch of a new product catalogue. Cytocell Technologies has now been fully integrated at the Cambridge laboratory and is soon to launch two new genetic testing product families. Cambridge BioScience has seen continued development of its existing product lines and has secured a number of new suppliers. The Company has been informed that one of its major suppliers, Molecular Probes Inc, which was recently acquired by Invitrogen Corporation, has indicated that it does not intend to
renew its distribution contract beyond the end of September 2004. We consider this to be a normal event in the trading cycle of Cambridge BioScience, as successful suppliers become attractive acquisition targets to multinationals in the market. In this regard Cambridge BioScience has entered into several new distribution agreements in the last six months that we expect to build on in the future."

The Company will also announce a number of management changes at the AGM. Dr. Umesh Patel will step down from the board of Cytomyx Holdings Plc and he will simultaneously be promoted to the position of Managing Director of Cytomyx Limited. Dr. Patel is a founder of Cytomyx Limited and has played a vital role in its development since inception. In his new role he will be responsible for all operational and commercial activities within this business unit. The Board thanks Dr. Patel for his contributions to-date and express their confidence in
his abilities to lead Cytomyx Limited in the future. As announced previously, Stephen Turner, the founder of Clinomics Biosciences has joined the board of Cytomyx Holdings Plc and remains CEO of Clinomics Biosciences.
Cytomyx also announces today that it has appointed Buchanan Communications to manage its investor relations activities in the UK. Cytomyx looks forward to increasing its profile in the investor community with the help of Buchanan
Communications who are one of the leading specialists in healthcare and life science financial PR. The Group is also exploring opportunities to develop an investor base in the USA. To facilitate this it has appointed The Wall Street Group in New York to initiate and manage US Investor Relations activities. Concluding Dr. Mason said, "The current year has started well with the
completion of an important acquisition and a fundraising. Although it is early in the year, trading is broadly in line with management`s expectations. I look forward to reporting on progress at the interim stage."

Contact
Theo Harold Cytomyx Holdings Plc 01223 508191
This information is provided by RNS
The company news service from the London Stock Exchange

END

AGMTAMPTMMTTBPI

[schakal23]

einsteigen bitte

[propus]

kann das bitte einer übersetzen oder mit
eigenen Worten wiedergeben.

Danke propus

[maronjj]

jetti bist sicher wieder zu 0,33 drinnen???
HAHAHAHAHAHA

[carlomania]

wo ist Jetti


schon Pleite

[carlomania]

London sammelt wieder

[maronjj]

wir werden weiter gehen!!!!!!!!!!!!!!!!!!

[jetti]

lo wieder tagestief und hier wird teuer eingekauft

[maronjj]

schaaaaaade zu spät!!!!!!!!!!!hahhahahahahahahahahahahahahahah

[schakal23]

da kommt wider ein bessen leben drin

[JacksonPenny]

Company Cytomyx Holdings PLC
26 Feb 2004

Cytomyx Holdings plc is pleased to announce that at the Annual General Meeting of the Company held today, all of the resolutions proposed were passed.

END

[Guru-Schreck]

#5

jetti widmet sich jetzt mehr dem nächsten Mega-Unterperformer isteel. Dies führte heute in
Hongkong zu einem Kursabschlag von etwa 27%.

[jetti]

guru...deine musik ist besser als dein gesabbel
bin seit 1,12 mit 11,5 kilo bei wcm

[moz01]

Britischer Pfund sieht auch nicht schlecht aus...

[Guru-Schreck]

#13

Du verwechselt da etwas, wie jederman in deinen Threads sehen kann, bist du wohl eher der, der etwas vor sich hin sabbelt. Wie soll man sonst das ewige fehthalten an einer Aktie werten, die klar ersichtlich den Markt megamässig unterperfomt hat. London sammelt wieder ....

[jetti]

und london fällt weiter !